Cardiology
|
June 27, 2024

How to Use Advanced Lipid Testing to Assess Your Cardiac Risk

Medically Reviewed by
Updated On
September 17, 2024

Cardiovascular disease (CVD) is the leading cause of mortality in the world, responsible for 17.9 million deaths annually and 31% of deaths globally. This article will discuss a crucial aspect of cardiac risk assessment: advanced lipid testing. 

While traditional cholesterol tests offer valuable insights, advanced lipid testing provides a more detailed look at cardiovascular health. This article describes how these tests function, what they measure, and, most importantly, how they empower individuals to understand and manage their cardiac risk.

[signup]

Traditional vs. Advanced Lipid Testing

The standard lipid panel includes total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides. 

While this panel is crucial for understanding CVD health, it has the potential to misclassify CVD risk, thereby leading to mismanagement and increased mortality (21).

Advanced lipid testing provides greater insight into CVD risk by assessing more specific lipid particles in the bloodstream. It evaluates the size, density, core lipid composition, and particular apolipoproteins involved in the pathogenesis of atherosclerosis and CVD (42). 

Key Components of Advanced Lipid Testing

The following advanced lipid markers are essential for assessing cardiovascular health.

LDL Particle Number (LDL-P) 

What is this marker?

Low-density lipoprotein particle number (LDL-P) measures the concentration of LDL particles in circulation. LDL-P plays a crucial role in atherosclerosis and cardiovascular disease progression and can be more accurate in diagnosing CVD risk than LDL cholesterol (45). 

Why is this an important marker to measure?

The development of atherosclerosis depends on inflammation levels (hs-CRP), insulin resistance, and lipid levels

LDL is the traditional biological marker for CVD risk. LDL does not account for insulin resistance and can be normal in patients who are still at risk for a cardiovascular event (stroke, heart attack, aneurysm). 

LDL-P is more accurate in predicting CVD risk than LDL because it measures the number of atherogenic particles in the blood (47). 

HDL Particle Size 

What is this marker?

High-density lipoprotein (HDL), or the "good cholesterol," assists in removing atherogenic lipids from the bloodstream. HDL particles can vary in size, with some larger and others smaller. 

The size of HDL particles is inversely related to the risk of CVD, with larger HDL particles associated with reduced cardiovascular risk and smaller HDL particles associated with increased risk of CVD (36). 

Why is this an important marker to measure?

Measuring HDL particle size can provide valuable insights into an individual's cardiovascular health and risk of heart disease. Understanding the size of HDL particles can help guide treatment more effectively. This test can also show variations in CVD risk for those with normal HDL levels (36). 

Lipoprotein(a), or Lp(a) 

What is this marker?

Lipoprotein (a), also known as Lp(a), is a form of LDL that is a genetic risk factor for developing atherosclerosis, coronary artery disease, thrombosis, and stroke. 

Lp(a) levels are highly correlated with LPA gene mutations. Lp(a) induces atherosclerosis by reducing fibrinolysis, a process that prevents blood clots from growing. Lp(a) also enhances the production of foam cells, which are responsible for plaque formation (26). 

Why is this an important marker to measure?

Lp(a) is an important screening tool for those with a family history of cardiovascular disease without other major risk factors. Lp(a) is considered one of the most atherogenic particles in circulation and helps identify patients who may need more intensive lipid-lowering therapy (26). 

Apolipoproteins ApoB and ApoA-I 

What are these markers?

Apolipoprotein B (ApoB) plays a chief role in plaque formation and contributes to atherogenesis and cardiovascular disease risk. ApoB is a carrier molecule for "bad" cholesterol, such as LDL, very low-density lipoprotein (VLDL), and low-density lipoprotein (IDL). 

ApoB levels indicate the atherogenic particle concentration of total cholesterol. It predicts cardiovascular disease risk more accurately than total or LDL cholesterol (7, 26). 

Apolipoprotein A1 (ApoA1) is the major protein component of HDL (good cholesterol). ApoA1 removes bad cholesterol from the body, assisting in the prevention of atherosclerosis. ApoA1 also plays a key role in mediating inflammation, immunity, and nitric oxide production (27). 

Why are these important markers to measure?

Measuring ApoB and ApoA1 is essential because an individual may have normal LDL and total cholesterol. An imbalance in the ApoB/ApoA1 ratio indicates an increased risk of cardiovascular disease. The ApoB/ApoA1 ratio is a more accurate predictor of cardiovascular disease risk in those with blood lipids within the normal range (39). 

How Advanced Lipid Testing Improves Cardiac Risk Assessment

Traditional lipid testing and comorbidities can be used to estimate an individual's 10-year risk for developing future cardiovascular disease. The current model of assessing CVD risk based on traditional lipid testing can misclassify up to 10% of patients. 

Incorporating advanced lipid testing may improve risk estimations and identify genetic disorders that may be missed with traditional lipid testing. Utilizing Lp(a) and LDLR gene testing can help identify genetic lipid disorders that would not be diagnosed with traditional lipid testing (9). 

Interpreting Advanced Lipid Test Results

Interpreting the results of advanced lipid tests can be complex. The following is a guide to understanding each value and its impact on cardiac health (28, 56):

  • LDL Particle Number: A measure of the concentration of LDL particles in circulation. Elevated levels are associated with an increased risk of CAD (even with normal LDL). Elevation in LDL-P should also prompt a workup for metabolic syndrome and insulin resistance
  • HDL Particle Size: Lower HDL particle size correlates with an increased risk of CVD. Practitioners want to see HDL particle size increasing throughout lipid-lowering treatment.
  • Lipoprotein (a) or Lp(a):  Lp(a) is an independent genetic risk factor for CVD, with little to no influence by lifestyle factors. Inflammatory conditions such as pregnancy, hypothyroidism, growth hormone therapy, and kidney disease may cause elevation.
  • ApoB & ApoA1 Ratio: These two markers are generally reported as a ratio. ApoB measures the particles that lead to atherosclerosis, and ApoA1 measures the particles within HDL particles, which aid in removing bad cholesterol from the body. A lower ratio correlates with a lower risk of CVD. 

Using Advanced Lipid Tests to Guide Treatment

Lifestyle Modifications

  • Regular physical activity increases HDL, aiding in eliminating LDL particles from circulation. To support healthy lipid levels, 150 minutes of moderate-intensity exercise per week is recommended. 
  • Obesity contributes to elevated lipids through various mechanisms. Weight loss and following a healthy diet increase the proportion of large HDL-P, which is associated with decreased CVD risk.
  • LDL particles are more sensitive to dietary modification than other lipid markers. Following a Mediterranean diet can help decrease the number of LDL particles in circulation. 
  • Reduce alcohol intake: For those with elevated lipid profiles, it is recommended to consume less than 10 g/day (1 drink).

(28)

Pharmacological Interventions

  • According to the ASCVD Risk Calculator, statin therapy is the first line of treatment for individuals whose LDL is greater than 190mg/dL, those with diabetes mellitus, and those 40-75 years of age at high risk (6).
  • PCSK9 inhibitors are recommended for patients with genetic familial hypercholesterolemia (LPA gene mutation, PCSK9 gene mutation, APOE gene mutation). 
  • For elevated Lp(a) levels, niacin, PCSK9 inhibitors, and Mipomersen have shown a reduction in Lp(a) levels. 
  • Nicotinic acid, statins, and bile acid sequestrants are recommended for patients with elevated LDL particle numbers. 
  • Statins show minimal effects on patients with decreased large HDL particle levels; thus, nicotinic acid and fibrates are recommended.
  • Bile acid sequestrants and nicotinic acid are recommended for patients with elevated ApoB levels. (46)

How to Get Advanced Lipid Testing

Rupa Health offers various options for advanced lipid testing:

[signup]

Key Takeaways

  • Advanced lipid testing offers a comprehensive cardiac risk assessment beyond a traditional cholesterol panel.
  • Analysis of LDL particle size, genetic mutations, and HDL functionality provides a more detailed understanding of individuals' risk factors for heart disease.
  • Incorporating lifestyle changes, such as physical exercise and proper diet, is essential in preventing cardiovascular disease.
  • Discuss advanced lipid testing with your provider to tailor specific strategies and treatment plans to enhance cardiovascular health.

Cardiovascular disease (CVD) is a leading cause of mortality worldwide, contributing to 17.9 million deaths annually and accounting for 31% of global deaths. This article will explore an important aspect of cardiac risk assessment: advanced lipid testing. 

While traditional cholesterol tests provide valuable insights, advanced lipid testing offers a more detailed perspective on cardiovascular health. This article explains how these tests work, what they measure, and how they can empower individuals to understand and manage their cardiac risk.

[signup]

Traditional vs. Advanced Lipid Testing

The standard lipid panel includes total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides. 

While this panel is important for understanding CVD health, it may not fully capture CVD risk, potentially leading to mismanagement (21).

Advanced lipid testing provides more detailed insights into CVD risk by assessing specific lipid particles in the bloodstream. It evaluates the size, density, core lipid composition, and particular apolipoproteins involved in the development of atherosclerosis and CVD (42). 

Key Components of Advanced Lipid Testing

The following advanced lipid markers are important for assessing cardiovascular health.

LDL Particle Number (LDL-P) 

What is this marker?

Low-density lipoprotein particle number (LDL-P) measures the concentration of LDL particles in circulation. LDL-P is involved in atherosclerosis and cardiovascular disease progression and may provide more accurate insights into CVD risk than LDL cholesterol (45). 

Why is this an important marker to measure?

The development of atherosclerosis is influenced by inflammation levels (hs-CRP), insulin resistance, and lipid levels

LDL is the traditional biological marker for CVD risk. LDL does not account for insulin resistance and can be normal in individuals who are still at risk for a cardiovascular event (stroke, heart attack, aneurysm). 

LDL-P may provide more accurate insights into CVD risk than LDL because it measures the number of atherogenic particles in the blood (47). 

HDL Particle Size 

What is this marker?

High-density lipoprotein (HDL), or the "good cholesterol," helps remove atherogenic lipids from the bloodstream. HDL particles can vary in size, with some larger and others smaller. 

The size of HDL particles is inversely related to the risk of CVD, with larger HDL particles potentially associated with reduced cardiovascular risk and smaller HDL particles potentially associated with increased risk of CVD (36). 

Why is this an important marker to measure?

Measuring HDL particle size can provide valuable insights into an individual's cardiovascular health and risk of heart disease. Understanding the size of HDL particles can help guide treatment more effectively. This test can also show variations in CVD risk for those with normal HDL levels (36). 

Lipoprotein(a), or Lp(a) 

What is this marker?

Lipoprotein (a), also known as Lp(a), is a form of LDL that is a genetic risk factor for developing atherosclerosis, coronary artery disease, thrombosis, and stroke. 

Lp(a) levels are highly correlated with LPA gene mutations. Lp(a) may influence atherosclerosis by affecting fibrinolysis, a process that helps manage blood clots. Lp(a) also influences the production of foam cells, which are involved in plaque formation (26). 

Why is this an important marker to measure?

Lp(a) is an important screening tool for those with a family history of cardiovascular disease without other major risk factors. Lp(a) is considered one of the most atherogenic particles in circulation and helps identify individuals who may benefit from more intensive lipid-lowering therapy (26). 

Apolipoproteins ApoB and ApoA-I 

What are these markers?

Apolipoprotein B (ApoB) plays a role in plaque formation and contributes to atherogenesis and cardiovascular disease risk. ApoB is a carrier molecule for "bad" cholesterol, such as LDL, very low-density lipoprotein (VLDL), and low-density lipoprotein (IDL). 

ApoB levels indicate the atherogenic particle concentration of total cholesterol. It may provide more accurate insights into cardiovascular disease risk than total or LDL cholesterol (7, 26). 

Apolipoprotein A1 (ApoA1) is the major protein component of HDL (good cholesterol). ApoA1 helps remove bad cholesterol from the body, supporting the management of atherosclerosis. ApoA1 also plays a role in mediating inflammation, immunity, and nitric oxide production (27). 

Why are these important markers to measure?

Measuring ApoB and ApoA1 is important because an individual may have normal LDL and total cholesterol. An imbalance in the ApoB/ApoA1 ratio may indicate an increased risk of cardiovascular disease. The ApoB/ApoA1 ratio may provide more accurate insights into cardiovascular disease risk in those with blood lipids within the normal range (39). 

How Advanced Lipid Testing Improves Cardiac Risk Assessment

Traditional lipid testing and comorbidities can be used to estimate an individual's 10-year risk for developing future cardiovascular disease. The current model of assessing CVD risk based on traditional lipid testing may not fully capture risk for up to 10% of individuals. 

Incorporating advanced lipid testing may improve risk estimations and help identify genetic disorders that may be missed with traditional lipid testing. Utilizing Lp(a) and LDLR gene testing can help identify genetic lipid disorders that may not be diagnosed with traditional lipid testing (9). 

Interpreting Advanced Lipid Test Results

Interpreting the results of advanced lipid tests can be complex. The following is a guide to understanding each value and its potential impact on cardiac health (28, 56):

  • LDL Particle Number: A measure of the concentration of LDL particles in circulation. Elevated levels may be associated with an increased risk of CAD (even with normal LDL). Elevation in LDL-P should also prompt a workup for metabolic syndrome and insulin resistance
  • HDL Particle Size: Lower HDL particle size may correlate with an increased risk of CVD. Practitioners may aim to see HDL particle size increasing throughout lipid-lowering treatment.
  • Lipoprotein (a) or Lp(a):  Lp(a) is an independent genetic risk factor for CVD, with little to no influence by lifestyle factors. Inflammatory conditions such as pregnancy, hypothyroidism, growth hormone therapy, and kidney disease may cause elevation.
  • ApoB & ApoA1 Ratio: These two markers are generally reported as a ratio. ApoB measures the particles that may lead to atherosclerosis, and ApoA1 measures the particles within HDL particles, which aid in removing bad cholesterol from the body. A lower ratio may correlate with a lower risk of CVD. 

Using Advanced Lipid Tests to Guide Treatment

Lifestyle Modifications

  • Regular physical activity may increase HDL, aiding in the management of LDL particles in circulation. To support healthy lipid levels, 150 minutes of moderate-intensity exercise per week is often suggested. 
  • Obesity may contribute to elevated lipids through various mechanisms. Weight loss and following a healthy diet may increase the proportion of large HDL-P, which is associated with decreased CVD risk.
  • LDL particles may be more sensitive to dietary modification than other lipid markers. Following a Mediterranean diet may help manage the number of LDL particles in circulation. 
  • Reducing alcohol intake: For those with elevated lipid profiles, it may be beneficial to consume less than 10 g/day (1 drink).

(28)

Pharmacological Interventions

  • According to the ASCVD Risk Calculator, statin therapy is often considered for individuals whose LDL is greater than 190mg/dL, those with diabetes mellitus, and those 40-75 years of age at high risk (6).
  • PCSK9 inhibitors may be recommended for patients with genetic familial hypercholesterolemia (LPA gene mutation, PCSK9 gene mutation, APOE gene mutation). 
  • For elevated Lp(a) levels, niacin, PCSK9 inhibitors, and Mipomersen have shown potential in managing Lp(a) levels. 
  • Nicotinic acid, statins, and bile acid sequestrants may be considered for patients with elevated LDL particle numbers. 
  • Statins may show minimal effects on patients with decreased large HDL particle levels; thus, nicotinic acid and fibrates may be recommended.
  • Bile acid sequestrants and nicotinic acid may be considered for patients with elevated ApoB levels. (46)

How to Get Advanced Lipid Testing

Rupa Health offers various options for advanced lipid testing:

[signup]

Key Takeaways

  • Advanced lipid testing offers a comprehensive cardiac risk assessment beyond a traditional cholesterol panel.
  • Analysis of LDL particle size, genetic mutations, and HDL functionality provides a more detailed understanding of individuals' risk factors for heart disease.
  • Incorporating lifestyle changes, such as physical exercise and proper diet, is important in supporting cardiovascular health.
  • Discuss advanced lipid testing with your healthcare provider to explore specific strategies and treatment plans to enhance cardiovascular health.
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

  1. Alebna, P. (n.d.). An Update on Lipoprotein(a): The Latest on Testing, Treatment, and Guideline Recommendations. American College of Cardiology. https://www.acc.org/Latest-in-Cardiology/Articles/2023/09/19/10/54/An-Update-on-Lipoprotein-a
  2. American College of Cardiology. (2021). ASCVD Risk Estimator. American College of Cardiology. https://tools.acc.org/ascvd-risk-estimator-plus/#
  3. Anderson, S. (2022, May 19). 6 Preventable Risk Factors Associated With Heart Attacks. Rupa Health. https://www.rupahealth.com/post/5-things-to-do-after-a-heart-attack
  4. APOA1. (n.d.). Rupa Health. Retrieved May 22, 2024, from https://www.rupahealth.com/biomarkers/apoa1  
  5. APOB. (n.d.). Rupa Health. Retrieved May 22, 2024, from https://www.rupahealth.com/biomarkers/apob
  6. Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., Michos, E. D., Miedema, M. D., Muñoz, D., Smith, S. C., Virani, S. S., Williams, K. A., Yeboah, J., & Ziaeian, B. (2019). 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. Circulation, 140(11). https://doi.org/10.1161/cir.0000000000000677
  7. Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021). Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. Metabolites, 11(10), 690. https://doi.org/10.3390/metabo11100690
  8. Bile Acid Resins or Sequestrants. (2012). PubMed; National Institute of Diabetes and Digestive and Kidney Diseases. https://www.ncbi.nlm.nih.gov/books/NBK548342/
  9. Brummel, K., Shah, N., & Stone, N. J. (2019). Advanced Lipid Thinking Prior to Incorporating Advanced Lipid Testing. ˜the œAmerican Journal of Medicine, 132(11), 1279–1284. https://doi.org/10.1016/j.amjmed.2019.05.034
  10. Bryant, A. (2024, January 31). How to Lower Blood Cholesterol Levels: Natural and Pharmacologic Options. Rupa Health. https://www.rupahealth.com/post/how-to-lower-blood-cholesterol-levels-natural-and-pharmacologic-options
  11. CardioMetabolic - Expanded by BostonHeart Diagnostics. (n.d.). Rupa Health. Retrieved May 22, 2024, from https://www.rupahealth.com/lab-tests/bostonheart-cardiometabolic-expanded#biomarkers
  12. Cardiovascular Risk Profile by Doctor's Data. (n.d.). Rupa Health. Retrieved May 22, 2024, from https://www.rupahealth.com/lab-tests/doctors-data-cardiovascular-risk-profile#biomarkers
  13. Cardiovascular Testing. (n.d.). Rupa Health. https://www.rupahealth.com/health-categories/cardiovascular
  14. Cloyd, J. (2023a, April 27). Unlocking the Health Benefits of Nitric Oxide: How This Molecule Supports Cardiovascular Health, Exercise Performance, and More. Rupa Health. https://www.rupahealth.com/post/nitric-oxide
  15. Cloyd, J. (2023b, May 1). A Functional Medicine Protocol for Coronary Artery Disease. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-protocol-for-coronary-artery-disease
  16. Cloyd, J. (2023c, June 19). A Functional Medicine Post Stroke Protocol: Testing, Therapeutic Diet, and Integrative Therapy Options. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-post-stroke-protocol-testing-supplements-and-integrative-therapy-options
  17. Cloyd, J. (2023d, December 5). Rupa Health. https://www.rupahealth.com/post/inflammation-and-heart-disease-a-functional-medicine-approach-to-prevention-and-treatment
  18. Cloyd, J. (2024a, March 5). How to Lower LDL Cholesterol Naturally: Evidence-Based Recommendations. Rupa Health. https://www.rupahealth.com/post/how-to-lower-ldl-cholesterol-naturally-evidence-based-recommendations
  19. Cloyd, J. (2024b, April 11). The Vicious Cycle of Obesity, Diabetes, and Hypertension: Breaking Free. Rupa Health. https://www.rupahealth.com/post/the-vicious-cycle-of-obesity-diabetes-and-hypertension-breaking-free
  20. Cloyd, K. (2023, December 19). How to interpret your lipid panel results. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-your-lipid-panel-results
  21. Cole, J., Sampson, M., Deventer, van, & Remaley, A. T. (2023). Reducing Lipid Panel Error Allowances to Improve the Accuracy of Cardiovascular Risk Stratification. Clinical Chemistry, 69(10), 1145–1154. https://doi.org/10.1093/clinchem/hvad109
  22. Daglis, S. (2024a, March 7). Emerging Biomarkers for Lipid Disorders: Beyond Traditional Lipid Profiles. Rupa Health. https://www.rupahealth.com/post/emerging-biomarkers-for-lipid-disorders-beyond-traditional-lipid-profiles
  23. Daglis, S. (2024b, March 12). Emerging Therapies for Lipid Disorders: PCSK9 Inhibitors and Beyond. Rupa Health. https://www.rupahealth.com/post/emerging-therapies-for-lipid-disorders-pcsk9-inhibitors-and-beyond
  24. Devaraj, S., Semaan, J. R., & Jialal, I. (2020). Biochemistry, Apolipoprotein B. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK538139/
  25. Diorio, B. (2023, January 17). Why Most Functional Medicine Practitioners Say No To Alcohol. Rupa Health. https://www.rupahealth.com/post/why-most-functional-medicine-practitioners-say-no-to-alcohol
  26. Farzam, K., & Senthilkumaran, S. (2021). Lipoprotein A. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK570621/
  27. Georgila, K., Vyrla, D., & Drakos, E. (2019). Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer. Cancers, 11(8), 1097. https://doi.org/10.3390/cancers11081097
  28. German, C. A., & Shapiro, M. D. (2020). Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science. European Cardiology Review, 15. https://doi.org/10.15420/ecr.2019.18
  29. Greenan, S. (2021, October 11). 7 Early Signs Of Insulin Resistance. Rupa Health. https://www.rupahealth.com/post/what-is-insulin-resistance
  30. Gui, Y., Zheng, H., & Cao, R. Y. (2022). Foam Cells in Atherosclerosis: Novel Insights Into Its Origins, Consequences, and Molecular Mechanisms. Frontiers in Cardiovascular Medicine, 9, 845942. https://doi.org/10.3389/fcvm.2022.845942
  31. Hamada, M., & Farzam, K. (2023). Mipomersen. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK592392/
  32. HDL-P. (n.d.). Rupa Health. Retrieved May 22, 2024, from https://www.rupahealth.com/biomarkers/hdl-p
  33. Khakham, C. (2023a, March 28). An integrative medicine approach to kidney disease. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-kidney-disease
  34. Khakham, C. (2023b, April 6). Understanding Your Risk of Cardiovascular Disease With Functional Medicine Labs. Rupa Health. https://www.rupahealth.com/post/understanding-your-risk-of-cardiovascular-disease-with-functional-medicine-labs
  35. Khakman, C. (2023, May 8). An Integrative and Functional Medicine Approach to Blood Clotting Disorders. Rupa Health. https://www.rupahealth.com/post/an-integrative-and-functional-medicine-approach-to-blood-clotting-disorders
  36. Kontush, A. (2015). HDL particle number and size as predictors of cardiovascular disease. Frontiers in Pharmacology, 6. https://doi.org/10.3389/fphar.2015.00218
  37. Lipoprotein (a). (n.d.). Rupa Health. Retrieved May 22, 2024, from https://www.rupahealth.com/biomarkers/lp-a
  38. Low-Density Lipoprotein Cholesterol. (n.d.). Rupa Health. Retrieved May 22, 2024, from https://www.rupahealth.com/biomarkers/ldl
  39. Lu, M., Lu, Q., Zhang, Y., & Tian, G. (2011). ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity. Journal of Biomedical Research, 25(4), 266–273. https://doi.org/10.1016/S1674-8301(11)60036-5
  40. Maholy, N. (2023a, May 10). A Functional Medicine Immune Support Protocol. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-immune-support-protocol
  41. Maholy, N. (2023b, May 23). A Functional Medicine Treatment Protocol for Metabolic Syndrome: Testing, Nutrition, and Supplements. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-treatment-protocol-for-metabolic-syndrome-testing-nutrition-and-supplements
  42. Nacimento Harada, P. H., & Akinkuolie, A. (n.d.). Advanced Lipoprotein Testing: Strengths and Limitations. American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2014/08/25/15/07/advanced-lipoprotein-testing-strengths-and-limitations
  43. National Institutes of Health. (2017). Office of Dietary Supplements - Niacin. Nih.gov. https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/
  44. Preston, J. (2023, September 22). Addressing Inflammation in Chronic Diseases: A Functional Medicine Perspective. Rupa Health. https://www.rupahealth.com/post/addressing-inflammation-in-chronic-diseases-a-functional-medicine-perspective
  45. Qiao, Y.-N., Zou, Y.-L., & Guo, S.-D. (2022). Low-density lipoprotein particles in atherosclerosis. Frontiers in Physiology, 13. https://doi.org/10.3389/fphys.2022.931931
  46. Quest Diagnostics. (n.d.). Cardio IQ ® Advanced Cardiovascular Testing Physician's Pocket Treatment Guide. https://www.questdiagnostics.com/healthcare-professionals/about-our-tests/cardiovascular/cardio-iq-report
  47. Rosenson, R. S., Davidson, M. H., & Pourfarzib, R. (2010). Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis, 213(1), 1–7. https://doi.org/10.1016/j.atherosclerosis.2010.03.038
  48. Singh, G., & Correa, R. (2020). Fibrate Medications. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK547756/
  49. Stanford, J. (2024, March 19). Exploring the Link Between Insulin Resistance and Obesity. Rupa Health. https://www.rupahealth.com/post/insulin-resistance-obesity
  50. Varanasi-Diaz, S. (2024, March 14). Integrating Pharmacology and A Root Cause Medicine Approach to Cardiovascular Care. Rupa Health. https://www.rupahealth.com/post/integrating-pharmacology-and-a-root-cause-medicine-approach-to-cardiovascular-care
  51. WALLDIUS, G., & JUNGNER, I. (2006). The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. Journal of Internal Medicine, 259(5), 493–519. https://doi.org/10.1111/j.1365-2796.2006.01643.x
  52. Warden, B. A., Fazio, S., & Shapiro, M. D. (2000). Familial Hypercholesterolemia: Genes and Beyond (K. R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, W. W. de Herder, K. Dungan, A. Grossman, J. M. Hershman, H. J. Hofland, G. Kaltsas, C. Koch, P. Kopp, M. Korbonits, R. McLachlan, J. E. Morley, M. New, J. Purnell, F. Singer, C. A. Stratakis, & D. L. Trence, Eds.). PubMed; MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK343488/
  53. Watts, G. F., Gidding, S. S., Hegele, R. A., Raal, F. J., Sturm, A. C., Jones, L. K., Sarkies, M. N., Khalid Al-Rasadi, Blom, D. J., Daccord, M., Sarah de Ferranti, Folco, E., Libby, P., Mata, P., Hapizah Nawawi, Ramaswami, U., Ray, K. K., Stefanutti, C., Yamashita, S., & Pang, J. (2023). International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. https://doi.org/10.1038/s41569-023-00892-0
  54. Weinberg, J. (2022, November 16). 4 Science Backed Health Benefits of The Mediterranean Diet. Rupa Health. https://www.rupahealth.com/post/4-science-backed-health-benefits-of-the-mediterranean-diet
  55. Weinberg, J. L. (2022, September 7). An Integrative Medicine Approach to Hypothyroidism. Rupa Health. https://www.rupahealth.com/post/understanding-hypothyroidism-and-how-to-treat-it-naturally
  56. What Is VLDL Cholesterol? (n.d.). Cleveland Clinic. https://my.clevelandclinic.org/health/articles/24540-vldl-cholesterol
  57. Yurth, E. (2021, July 20). How to Identify Risk for Cardiovascular Disease Using ApoB/ApoA1 Blood Testing. Rupa Health. https://www.rupahealth.com/post/how-to-identify-risk-for-cardiovascular-disease-using-apob-apoa1-blood-testing
Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.

Latest Articles

View more on Cardiology
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
Visit Source
National Library of Medicine
Government Authority
Visit Source
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
Visit Source
National Cancer Institute
Government Authority
Visit Source
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
Visit Source
CDC
Government Authority
Visit Source
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
Visit Source
National Institutes of Health
Government Authority
Visit Source
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Visit Source
Brain
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Chest
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source
Visit Source

Hey Practitioners! On December 11th, join Dr. Terry Wahls in a free live class where she'll share her groundbreaking methods for managing MS and autoimmune patients. This live session will address your most pressing questions and will take a closer look at treatment options beyond the conventional standards of care. Register here.

Register Here